StreetInsider.com News Articles

Form 6-K PRF Technologies Ltd. For: Jul 27

Mon, 27 Jul 2026 08:48:00 -0400

si-local-file:///var/storage/secattach/20260727/26816779.html

Form 6-K PRF Technologies Ltd. For: Jul 27

Mon, 27 Jul 2026 08:48:00 -0400

si-local-file:///var/storage/secattach/20260727/26816779.html

PRF Technologies raises $10M and updates progress on biotech and energy

Mon, 27 Jul 2026 08:30:54 -0400

PRF Technologies Ltd. (Nasdaq: PRFX), an Israel-based company with biotechnology and AI-driven energy operations, issued a shareholder letter from Interim Chief Executive Officer Efraim Cohen-Arazi outlining first-half 2026 developments.

On May 28, 2026, the company raised $10 million through its equity line facility, which it said strengthened its balance sheet and provides capital to support its existing businesses and potential strategic opportunities.

In its biotechnology segment, majority-owned subsidiary LayerBio, Inc. is advancing preparations for a planned Phase 2 clinical trial of OcuRing-K, a sustained-release anti-inflammatory implant designed for placement on the intraocular lens during cataract surgery. In June 2026, the company reported

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF”, “PRF Technologies” or the “Company”) today issued a Letter to Shareholders from Efraim Cohen-Arazi, Interim Chief Executive Officer.

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Mon, 27 Jul 2026 08:30:00 -0400

First-Half 2026 and Recent Highlights:

Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
DeepSolar validated its Predict™ platform

Form 6-K PRF Technologies Ltd. For: Jul 21

Tue, 21 Jul 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260721/26792944.html

Form 6-K PRF Technologies Ltd. For: Jul 21

Tue, 21 Jul 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260721/26792944.html

PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026